drugset / Trial / NCT01502124

Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency

NCT01502124

Phase 3 Completed 78 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.

Timeline

Start
2001-05-08
Primary completion
2003-03-05
Completion
2003-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.024 mg/kg Subcutaneous
Subject Somatropin Protein / enzyme biologic 0.05 mg/kg Subcutaneous